Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia

ConclusionsThere were no differences between blonanserin and aripiprazole in the improvement of clinical symptoms. Our results suggest that pHVA may be useful indicator for the switching strategy to aripiprazole or blonanserin in schizophrenia. Copyright © 2014 John Wiley & Sons, Ltd.

Source: Human Psychopharmacology: Clinical and Experimental - January 8, 2014 Category: Psychiatry Authors: Itaru Miura, Tetsuya Shiga, Akihiko Katsumi, Keiko Kanno‐Nozaki, Hirobumi Mashiko, Shin‐Ichi Niwa, Hirooki Yabe Tags: Short Communication Source Type: research